20.01.2006 13:07:00
|
Elsevier Announces iCONSULT to be Offered as Part of Epic Electronic Health Record
PHILADELPHIA, January 20 /PRNewswire/ --
- Partnership Puts FIRST Consult and Other Evidence-Based Clinical Information Directly Into Electronic Health Record Service for Hospitals and Medical Practices
Elsevier, a world-leading medical publisher, today announced a strategic partnership to deliver Elsevier's iCONSULT service directly to the hospital and group medical practice community as part of Epic Systems Corporation's electronic health record. iCONSULT delivers real-time clinical decision support by putting evidence-based, point-of-care clinical reference content directly into the electronic workflow of health practitioners. The combination of these offerings enhances solutions that help healthcare providers support best practices and reduce healthcare costs.
"This partnership of a world-class content provider with an industry-leading EHR vendor is exactly what healthcare organizations need for their medical staff," says Charles Safran, M.D., Associate Clinical Professor of Medicine, Harvard Medical School and iCONSULT Advisory Board member. "iCONSULT's ability to deliver concise, evidence-based information directly into the electronic health record can help reduce errors and drive EHR adoption in today's rapidly evolving healthcare environment."
Elsevier, a world-leading science and medical publisher, developed iCONSULT to integrate its clinical reference content directly into the electronic workflow and enhance clinical decision support. Content is indexed against industry standard clinical vocabularies, patient demographics and organized around the clinician's workflow, allowing iCONSULT to deliver rapid answers to specific patient scenarios directly into the electronic health record. Products offered via the iCONSULT service include:
- FIRST Consult, Elsevier's premier point of care, evidence based medical reference tool, indexed by ICD9-CM codes, and updated weekly to offer information on evaluation, diagnosis and treatment of a variety of disease categories. - MD Consult, the leading industry medical reference database, allowing users to seamlessly search and access clinical information
"This partnership is an absolute victory for health practitioners and will change the way they consume medical information to support their clinical decisions. Valuable partnerships like this are very important to our overall strategy of putting more and more relevant clinical information directly at the point of care," says Brian Nairn, CEO, Elsevier, Health Science Division.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in 74 offices worldwide publish more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as MD Consult (http://www.mdconsult.com ), ScienceDirect ( http://www.sciencedirect.com ), Scopus (http://www.info.scopus.com/ ), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com ) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com ), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Web site: http://www.elsevier.com http://www.mdconsult.com http://www.reedelsevier.com http://www.info.scopus.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Reed Elsevier plc (Spons. ADRs)mehr Nachrichten
Keine Nachrichten verfügbar. |